Technology
Health
Medical

Penumbra

$157.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.35 (-1.47%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Penumbra and other stocks, options, ETFs, and crypto commission-free!

About

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Read More Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Employees
2,200
Headquarters
Alameda, California
Founded
2004
Market Cap
5.52B
Price-Earnings Ratio
1.04K
Dividend Yield
0.00
Average Volume
348.05K
High Today
$162.50
Low Today
$157.89
Open Price
$160.75
Volume
219.34K
52 Week High
$167.35
52 Week Low
$110.84

Collections

Technology
Health
Medical
Advertising and Marketing
Medical Devices
Business Services
2015 IPO
US

News

MarketBeatMar 7

NYSE:PEN - Stock Price, News, & Analysis for Penumbra

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System un...

24
Yahoo FinanceMar 4

Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4

Penumbra, Inc. PEN reported fourth-quarter 2018 earnings per share (EPS) of 13 cents, up 30% year over year. The figure surpassed the Zacks Consensus Estimate of 11 cents by 18.2%. However, the stock movement does not reflect the company’s promising earnings results as it lost 4.2% to close at $140.52 on Mar 1 since the release. The company reported 2018 adjusted earnings of 51 cents, beating the Zacks Consensus Estimate by 6.3%. The figure also compares favorably with the year-ago loss of a penny. Revenu...

34
Simply Wall StFeb 27

How Do Penumbra, Inc.’s (NYSE:PEN) Returns Compare To Its Industry?

Today we’ll evaluate Penumbra, Inc. (NYSE:PEN) to determine whether it could have potential as an investment idea. Specifically, we’re going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. First up, we’ll look at what ROCE is and how we calculate it. Second, we’ll look at its ROCE compared to similar companies. And finally, we’ll look at how its current liabilities are impacting its ROCE. What is Return On Capital Employed (ROCE)? ROCE measures ...

31

Earnings

-$0.06
$0.02
$0.09
$0.17
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.